-+ 0.00%
-+ 0.00%
-+ 0.00%

Ingenia Therapeutics files FDA IND for IGT-303 Phase 1/2a CKD trial in US

PUBT·09/28/2026 08:32:17
Listen to the news
Ingenia Therapeutics files FDA IND for IGT-303 Phase 1/2a CKD trial in US
  • Ingenia Therapeutics filed an IND with the FDA on Sept. 25, 2026 for IGT-303 in chronic kidney disease.
  • The Phase 1/2a trial targets 94 participants across five U.S. sites, including healthy volunteers and CKD patients.
  • Study will assess safety, tolerability, pharmacokinetics; dosing via IV or subcutaneous injection with placebo control.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingenia Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260928900646), on September 28, 2026, and is solely responsible for the information contained therein.